Newly diagnosed CNS lymphoma with orelabrutinib combination therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–75 years old.
- You must have newly diagnosed primary central nervous system lymphoma that has not been treated before.
- You must be able to walk and care for yourself (ECOG score 0–3).
- Your blood counts, liver, and kidney function must be within certain limits.
- You must be willing to have a lumbar puncture (spinal tap) or have a small reservoir in your head for medicines.
- You cannot have lymphoma outside your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests combining a targeted drug (orelabrutinib) with standard chemo (R-CHOP plus methotrexate or thiotepa) for people whose DLBCL has spread to the brain or spinal cord. The goal is to see if this combination works better against hard-to-treat lymphoma.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.